HK1131126A1 - Fused cyclic compounds - Google Patents

Fused cyclic compounds

Info

Publication number
HK1131126A1
HK1131126A1 HK09109075.0A HK09109075A HK1131126A1 HK 1131126 A1 HK1131126 A1 HK 1131126A1 HK 09109075 A HK09109075 A HK 09109075A HK 1131126 A1 HK1131126 A1 HK 1131126A1
Authority
HK
Hong Kong
Prior art keywords
cyclic compounds
fused cyclic
fused
compounds
cyclic
Prior art date
Application number
HK09109075.0A
Other languages
English (en)
Inventor
Tsuneo Yasuma
Nobuyuki Negoro
Masayuki Yamashita
Masahiro Itou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of HK1131126A1 publication Critical patent/HK1131126A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Psychiatry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Communicable Diseases (AREA)
  • Reproductive Health (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Pulmonology (AREA)
HK09109075.0A 2006-06-27 2009-09-30 Fused cyclic compounds HK1131126A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006177099 2006-06-27
PCT/JP2007/063208 WO2008001931A2 (en) 2006-06-27 2007-06-26 Fused cyclic compounds

Publications (1)

Publication Number Publication Date
HK1131126A1 true HK1131126A1 (en) 2010-01-15

Family

ID=38656568

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09109075.0A HK1131126A1 (en) 2006-06-27 2009-09-30 Fused cyclic compounds

Country Status (37)

Country Link
US (5) US7732626B2 (pt)
EP (4) EP2248812B1 (pt)
JP (3) JP4401428B2 (pt)
KR (1) KR101058772B1 (pt)
CN (4) CN103070854A (pt)
AR (1) AR061644A1 (pt)
AT (1) ATE543815T1 (pt)
AU (1) AU2007265966B2 (pt)
BR (1) BRPI0713378A8 (pt)
CA (2) CA2838448A1 (pt)
CL (1) CL2007001873A1 (pt)
CO (1) CO6160234A2 (pt)
CR (1) CR10564A (pt)
CY (2) CY1112705T1 (pt)
DK (2) DK2041123T3 (pt)
ES (2) ES2450081T3 (pt)
GE (1) GEP20115359B (pt)
HK (1) HK1131126A1 (pt)
HR (2) HRP20120333T1 (pt)
IL (1) IL195947A (pt)
JO (1) JO2969B1 (pt)
MA (1) MA30537B1 (pt)
ME (1) ME00535B (pt)
MX (1) MX2008016274A (pt)
MY (1) MY154798A (pt)
NO (1) NO20090235L (pt)
NZ (1) NZ574038A (pt)
PE (1) PE20080993A1 (pt)
PL (2) PL2248812T3 (pt)
PT (2) PT2248812E (pt)
RS (2) RS53230B (pt)
RU (1) RU2444521C2 (pt)
SI (2) SI2248812T1 (pt)
TW (1) TWI354668B (pt)
UA (1) UA95296C2 (pt)
WO (1) WO2008001931A2 (pt)
ZA (1) ZA200900154B (pt)

Families Citing this family (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
EP2205548A1 (en) 2007-10-10 2010-07-14 Amgen, Inc Substituted biphenyl gpr40 modulators
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
JP2012503595A (ja) 2008-07-28 2012-02-09 シダンスク ユニバーシティ 代謝病の治療用の化合物
UY32126A (es) 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida
EP2358656B1 (en) 2008-10-15 2014-01-01 Amgen, Inc Spirocyclic gpr40 modulators
EP2351743A4 (en) 2008-10-27 2012-05-09 Takeda Pharmaceutical BICYCLIC CONNECTION
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
JPWO2010076884A1 (ja) 2008-12-29 2012-06-21 武田薬品工業株式会社 新規縮合環化合物およびその用途
WO2010087467A1 (en) 2009-01-27 2010-08-05 Takeda Pharmaceutical Company Limited Delta-5-desaturase inhibitors
WO2010123016A1 (ja) 2009-04-22 2010-10-28 アステラス製薬株式会社 カルボン酸化合物
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
SG178062A1 (en) 2009-07-28 2012-03-29 Takeda Pharmaceutical Tablet
AU2010312365A1 (en) 2009-10-30 2012-06-07 Mochida Pharmaceutical Co.,Ltd. Novel 3-hydroxy-5-arylisoxazole derivative
MA33952B1 (fr) 2009-12-25 2013-01-02 Mochida Pharmacal Co Ltd Nouveau dérivé 3 -hydroxy- 5-arylisothiazole
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
JP5693611B2 (ja) 2010-04-27 2015-04-01 武田薬品工業株式会社 二環性化合物
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
CN103068816B (zh) 2010-06-16 2015-01-07 武田药品工业株式会社 酰胺化合物的结晶
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
WO2012036293A1 (ja) 2010-09-17 2012-03-22 武田薬品工業株式会社 糖尿病治療剤
CA2813639A1 (en) 2010-10-08 2012-04-12 Mochida Pharmaceutical Co. Ltd. Cyclic amide derivative
BR112013013417A2 (pt) 2010-11-30 2019-09-24 Takeda Pharmaceuticals Co composto, medicamento, métodos para inibir a acetil-coa carboxilase em um mamífero, e de profilaxia ou tratamento da obesidade ou diabete em um mamífero, e, uso de um composto ou sal
EP2646425B1 (en) 2010-12-01 2015-06-10 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
EP2675774A1 (en) 2011-02-17 2013-12-25 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
JP6054368B2 (ja) 2011-04-08 2016-12-27 カルダン セラピューティクス リミテッドＣａｌｄａｎ Ｔｈｅｒａｐｅｕｔｉｃｓ Ｌｉｍｉｔｅｄ 代謝性疾患治療用ｏ−フルオロ置換化合物またはその塩
KR20140021624A (ko) 2011-04-27 2014-02-20 모찌다 세이야쿠 가부시끼가이샤 신규 3-히드록시이소티아졸 1-옥시드 유도체
US9072758B2 (en) 2011-04-28 2015-07-07 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) * 2011-09-26 2015-04-08 上海恒瑞医药有限公司 稠合环类衍生物、其制备方法及其在医药上的应用
WO2013045413A1 (en) 2011-09-27 2013-04-04 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013061962A1 (ja) 2011-10-24 2013-05-02 武田薬品工業株式会社 二環性化合物
EP2802571A1 (en) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
RU2621039C1 (ru) * 2012-01-12 2017-05-31 Цзянсу Хэнжуй Медсин Ко., Лтд. Полициклические производные, способ их получения и их фармацевтическое применение
GB2498968A (en) * 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
EP2816023A4 (en) 2012-02-13 2015-09-09 Takeda Pharmaceutical AROMATIC CORE COMPOUND
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
CA2864068A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet comprising 1-(4-methoxybutyl)-n-(2-methylpropyl)-n-[(3s,5r)-5-(morpholin-4-ylcarbonyl)piperidin-3-yl]-1h-benzimidazole-2-carboxamide or a salt thereof
CN104254525B (zh) * 2012-02-24 2016-05-25 武田药品工业株式会社 芳环化合物
CA2866210A1 (en) 2012-02-28 2013-09-06 Piramal Enterprises Limited Phenyl alkanoic acid derivatives as gpr agonists
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
JPWO2013147026A1 (ja) 2012-03-29 2015-12-14 武田薬品工業株式会社 芳香環化合物
US8809376B2 (en) 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
US9440987B2 (en) 2012-05-10 2016-09-13 Takeda Pharmaceutical Company Limited Aromatic ring compound
EP2848622A4 (en) 2012-05-10 2015-11-04 Takeda Pharmaceutical AROMATIC RING CONNECTION
UY34847A (es) 2012-06-05 2014-01-31 Takeda Pharmaceutical Preparacion sólida
CN104780915A (zh) 2012-07-11 2015-07-15 埃尔舍利克斯治疗公司 包含他汀、双胍和用于减小心脏代谢风险的其它药剂的组合物
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
DK2894151T3 (da) 2012-09-04 2021-01-11 Shanghai hengrui pharmaceutical co ltd Imidazolinderivater, fremgangsmåder til fremstilling deraf og anvendelse deraf i medicin
US20150297573A1 (en) 2012-10-24 2015-10-22 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING Beta-CELL SURVIVAL
TWI692469B (zh) 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
HUE032401T2 (en) 2012-11-16 2017-09-28 Bristol Myers Squibb Co Dihydropyrazole GPR40 modulators
AP2015008364A0 (en) 2012-11-28 2015-04-30 Boehringer Ingelheim Int New idanyloxydihydrobenzof uranylacetic acids
WO2014086712A1 (en) 2012-12-07 2014-06-12 Boehringer Ingelheim International Gmbh New indanyloxydihydrobenzofuranylacetic acids
JP6314335B2 (ja) 2013-02-06 2018-04-25 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新しいインダニルオキシジヒドロベンゾフラニル酢酸
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
ES2709195T3 (es) * 2013-02-28 2019-04-15 Tiumbio Co Ltd Compuesto tricíclico y uso del mismo
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
ES2629729T3 (es) 2013-03-14 2017-08-14 Takeda Pharmaceutical Company Limited Derivados de espiro azetidina asoxazol y uso de los mismos como antagonistas de sstr5
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
CN104870429B (zh) * 2013-05-22 2017-05-03 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) * 2013-06-25 2017-12-26 南京圣和药业股份有限公司 Gpr40激动剂及其应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
CN104507921B (zh) * 2013-07-02 2017-02-22 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
JP2016523809A (ja) 2013-07-09 2016-08-12 武田薬品工業株式会社 複素環化合物
PT3031799T (pt) 2013-08-09 2018-07-04 Takeda Pharmaceuticals Co Composto aromático
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
WO2015032328A1 (zh) * 2013-09-03 2015-03-12 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104592211B (zh) * 2013-10-31 2018-10-16 广东东阳光药业有限公司 联苯类化合物及其用途
IN2013MU03577A (pt) 2013-11-14 2015-07-31 Cadila Healthcare Ltd
US10519115B2 (en) 2013-11-15 2019-12-31 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
US9957219B2 (en) 2013-12-04 2018-05-01 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
WO2015119899A1 (en) 2014-02-06 2015-08-13 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2016022742A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
WO2016060517A2 (ko) * 2014-10-17 2016-04-21 현대약품 주식회사 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
ES2805743T3 (es) 2015-03-24 2021-02-15 Inst Nat Sante Rech Med Método y composición farmacéutica para uso en el tratamiento de la diabetes
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
US10676458B2 (en) 2016-03-29 2020-06-09 Merch Sharp & Dohne Corp. Rahway Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
EP3573953A1 (en) 2017-01-26 2019-12-04 Boehringer Ingelheim International GmbH Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10603317B2 (en) 2017-01-26 2020-03-31 Boehringer Ingelheim International Gmbh Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
WO2018138028A1 (en) 2017-01-26 2018-08-02 Boehringer Ingelheim International Gmbh Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
JP7049353B2 (ja) 2017-02-08 2022-04-06 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 糖尿病の治療のためのインダニルアミノアザジヒドロベンゾフラニル酢酸、医薬組成物
JOP20180029A1 (ar) 2017-03-30 2019-01-30 Takeda Pharmaceuticals Co مركب حلقي غير متجانس
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
CA3058578A1 (en) 2017-03-31 2018-10-04 Takeda Pharmaceutical Company Limited Aromatic compound
JOP20180028A1 (ar) 2017-03-31 2019-01-30 Takeda Pharmaceuticals Co مركب ببتيد
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. BICYCLIC ANTIDIABETIC COMPOUNDS
WO2019134984A1 (en) 2018-01-08 2019-07-11 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as gpr40 agonists
SI3752501T1 (sl) 2018-02-13 2023-08-31 Gilead Sciences, Inc. Inhibitorji pd-1/pd-l1
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
US11535660B1 (en) 2018-03-23 2022-12-27 Cannot Therapeutics, Inc. Modulators of G-protein coupled receptors
US10899735B2 (en) 2018-04-19 2021-01-26 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
TWI809427B (zh) 2018-07-13 2023-07-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
JP6773938B2 (ja) 2018-08-27 2020-10-21 株式会社スコヒアファーマ 安息香酸エステル化合物
EP3856768A2 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
WO2020086556A1 (en) 2018-10-24 2020-04-30 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
WO2022034664A1 (ja) * 2020-08-12 2022-02-17 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
JP7507486B2 (ja) * 2019-02-13 2024-06-28 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
EP4126920A2 (en) 2020-03-25 2023-02-08 Takeda Pharmaceutical Company Limited Gif receptor agonist peptide compounds and uses thereof
IL296592A (en) 2020-03-25 2022-11-01 Takeda Pharmaceuticals Co One-day doses of gip receptor agonistic peptides and their uses
US20240067603A1 (en) * 2020-12-16 2024-02-29 Regents Of The University Of Minnesota Cubanyl biguanide compounds
CN117980325A (zh) 2021-05-13 2024-05-03 卡莫特治疗学股份有限公司 G-蛋白偶联受体的调节剂
WO2023169456A1 (en) 2022-03-09 2023-09-14 Gasherbrum Bio , Inc. Heterocyclic glp-1 agonists
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024125602A1 (en) 2022-12-15 2024-06-20 Gasherbrum Bio, Inc. Salts and solid forms of a compound having glp-1 agonist activity
WO2024131869A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024138048A1 (en) 2022-12-22 2024-06-27 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
WO2024169952A1 (en) 2023-02-16 2024-08-22 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5612330A (en) 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
RU6023U1 (ru) 1997-01-20 1998-02-16 АО "Автоэлектроника" Устройство управления для экономайзера принудительного холостого хода
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
WO1999022735A1 (en) 1997-10-30 1999-05-14 Merck & Co., Inc. Somatostatin agonists
HUP0200997A3 (en) 1999-04-28 2003-03-28 Sanofi Aventis Deutschland Tri-aryl acid derivatives as ppar receptor ligands and pharmaceutical compositions containing them
RU11297U1 (ru) 1999-06-16 1999-09-16 Курзанов Евгений Владимирович Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
ATE309995T1 (de) 1999-08-26 2005-12-15 Aventis Pharma Inc Substituierte (aminoiminomethyl oder aminomethyl) dihydrobenzofurane und benozopyrane
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMIN DERIVATIVES
AU780948C (en) 1999-11-10 2006-09-14 Takeda Pharmaceutical Company Limited 5-membered N-heterocyclic compounds with hypoglycemic and hypolipidemic activity
DE60018216T2 (de) * 1999-12-24 2006-02-16 Kyowa Hakko Kogyo Co., Ltd. Kondensierte purinderivate
ATE479429T1 (de) 2000-04-28 2010-09-15 Takeda Pharmaceutical Antagonisten des melanin-konzentrierenden hormons
WO2001087834A1 (fr) 2000-05-16 2001-11-22 Takeda Chemical Industries, Ltd. Antagoniste de l'hormone de concentration de la melanine
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
ATE326458T1 (de) * 2000-09-15 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinasehemmer
RU2340611C2 (ru) 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
DK1353916T3 (da) * 2000-12-21 2007-01-29 Vertex Pharma Pyrazolforbindelser der er egnede som proteinkinaseinhibitorer
AU2001297625A1 (en) * 2000-12-21 2002-09-12 Bristol-Myers Squibb Company Nucleic acid molecules and polypeptides for a human cation channel polypeptide
UA73236C2 (en) * 2001-03-30 2005-06-15 Pfizer Prod Inc Pyridasinones having properties of aldosereductase inhibitors
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
TW522326B (en) * 2001-08-03 2003-03-01 Inventec Corp Real-time data customer service system and method thereof
US6701066B2 (en) * 2001-10-11 2004-03-02 Micron Technology, Inc. Delivery of solid chemical precursors
US20050245571A1 (en) 2001-10-19 2005-11-03 Hidenori Abe Amine derivative
JP4166024B2 (ja) 2002-03-07 2008-10-15 独立行政法人科学技術振興機構 ２環式化合物およびその製造方法
UA80427C2 (en) * 2002-04-26 2007-09-25 Hoffmann La Roche Substituted phenylacetamides and their use as glucokinase activators
WO2004011469A1 (ja) * 2002-07-26 2004-02-05 Kyowa Hakko Kogyo Co., Ltd. 細胞分化誘導剤
US7960369B2 (en) 2002-11-08 2011-06-14 Takeda Pharmaceutical Company Limited Receptor function regulator
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
EP1604971A4 (en) 2003-03-11 2006-08-16 Ono Pharmaceutical Co PROCESS FOR ADDING ACTIVE CHARCOAL IN WATER PURIFICATION AND WATER PURIFICATION METHOD
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONNECTION WITH CONDENSED RING
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
RU2353617C2 (ru) 2003-10-31 2009-04-27 Такеда Фармасьютикал Компани Лимитед Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
US7834013B2 (en) 2003-11-19 2010-11-16 Glaxosmithkline Llc Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to GPR40
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
TW200523247A (en) * 2003-12-25 2005-07-16 Takeda Pharmaceutical 3-(4-benzyloxyphenyl) propanoic acid derivatives
JP4855777B2 (ja) 2003-12-26 2012-01-18 武田薬品工業株式会社 フェニルプロパン酸誘導体
EP1726580A4 (en) 2004-03-15 2008-02-13 Takeda Pharmaceutical AMINOPHNYLPROPANO ACID DERIVATIVE
EP1731505B1 (en) * 2004-03-30 2015-01-14 Takeda Pharmaceutical Company Limited Alkoxyphenylpropanoic acid derivatives
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
JP3689711B1 (ja) 2004-12-24 2005-08-31 極東鋼弦コンクリート振興株式会社 真空グラウト注入方法
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
AR055563A1 (es) * 2005-02-25 2007-08-22 Takeda Pharmaceutical Compuestos de piridil acido acetico, agente farmaceutico y utilizacion del compuesto para preparar dicho agente
PE20080212A1 (es) 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)
TW200815418A (en) 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application

Also Published As

Publication number Publication date
CN102731451B (zh) 2015-07-29
EP2743268A2 (en) 2014-06-18
CA2656003A1 (en) 2008-01-03
CN101616913A (zh) 2009-12-30
JP4917634B2 (ja) 2012-04-18
AR061644A1 (es) 2008-09-10
WO2008001931A3 (en) 2009-09-11
DK2248812T5 (da) 2015-01-26
EP2248812B1 (en) 2013-12-25
CY1112705T1 (el) 2016-02-10
MA30537B1 (fr) 2009-06-01
JP2012062320A (ja) 2012-03-29
KR20090027743A (ko) 2009-03-17
BRPI0713378A2 (pt) 2012-04-03
RS53230B (en) 2014-08-29
EP2431367A3 (en) 2012-07-04
GEP20115359B (en) 2011-12-26
EP2041123B1 (en) 2012-02-01
EP2041123A2 (en) 2009-04-01
AU2007265966A1 (en) 2008-01-03
AU2007265966B2 (en) 2012-05-17
SI2248812T1 (sl) 2014-04-30
EP2041123B9 (en) 2013-01-02
PL2041123T3 (pl) 2012-09-28
NO20090235L (no) 2009-02-16
JP4401428B2 (ja) 2010-01-20
CA2838448A1 (en) 2008-01-03
JP2009280595A (ja) 2009-12-03
CA2656003C (en) 2014-03-25
US20130267589A1 (en) 2013-10-10
CL2007001873A1 (es) 2008-01-04
NZ574038A (en) 2011-12-22
ES2379661T3 (es) 2012-04-30
SI2041123T1 (sl) 2012-05-31
US20140080891A1 (en) 2014-03-20
ME00535B (me) 2011-10-10
CN102731451A (zh) 2012-10-17
RS52307B (en) 2012-12-31
JP2009542580A (ja) 2009-12-03
WO2008001931A2 (en) 2008-01-03
PT2248812E (pt) 2014-03-12
US8598226B2 (en) 2013-12-03
IL195947A0 (en) 2009-09-01
RU2444521C2 (ru) 2012-03-10
HRP20120333T1 (hr) 2012-05-31
US20100197761A1 (en) 2010-08-05
RU2009102515A (ru) 2010-08-10
US20120046338A1 (en) 2012-02-23
MY154798A (en) 2015-07-31
HRP20140201T1 (hr) 2014-04-11
DK2248812T3 (da) 2014-03-10
MX2008016274A (es) 2009-01-15
CO6160234A2 (es) 2010-05-20
ATE543815T1 (de) 2012-02-15
PL2248812T3 (pl) 2014-07-31
US8088821B2 (en) 2012-01-03
CR10564A (es) 2012-06-18
PT2041123E (pt) 2012-04-09
EP2248812A3 (en) 2011-03-16
CN101616913B (zh) 2013-01-23
EP2431367A2 (en) 2012-03-21
JP5409757B2 (ja) 2014-02-05
TWI354668B (en) 2011-12-21
DK2041123T3 (da) 2012-05-07
UA95296C2 (uk) 2011-07-25
EP2743268A3 (en) 2014-10-08
BRPI0713378A8 (pt) 2018-01-02
TW200811125A (en) 2008-03-01
CN103083307A (zh) 2013-05-08
US8492430B2 (en) 2013-07-23
JO2969B1 (en) 2016-03-15
ZA200900154B (en) 2010-03-31
PE20080993A1 (es) 2008-10-06
EP2248812A2 (en) 2010-11-10
ES2450081T3 (es) 2014-03-21
KR101058772B1 (ko) 2011-08-24
US20100004312A1 (en) 2010-01-07
US7732626B2 (en) 2010-06-08
IL195947A (en) 2013-07-31
CY1114978T1 (el) 2016-12-14
CN103070854A (zh) 2013-05-01

Similar Documents

Publication Publication Date Title
HUS1900033I1 (hu) Szubsztituált enaminokarbonil vegyületek
ZA200900154B (en) Fused cyclic compounds
GB0602424D0 (en) Compounds
GB0602046D0 (en) Compounds
EP1984379A4 (en) ANTI-ARENAVIRAL COMPOUNDS
EP2082022A4 (en) COMPOUNDS
EP2004174A4 (en) NAPHTHALENEDIONED COMPOUNDS
GB0602042D0 (en) Compounds
EP1973905A4 (en) COMPOUNDS
ZA200901570B (en) Substituted azolin-2-YL-amino compounds
EP2016069A4 (en) BISPYRIDINIUMVERBINDUNGEN
GB0602560D0 (en) Compounds
GB0602412D0 (en) Compounds
GB0600427D0 (en) Compounds
GB0624758D0 (en) Novel cyclic compounds
GB0725272D0 (en) Novel cyclic compounds
GB0605414D0 (en) Compounds
GB0605410D0 (en) Compounds
GB0604377D0 (en) Compounds
GB0604375D0 (en) Compounds
GB0603551D0 (en) Compounds
GB0603133D0 (en) Compounds
GB0603132D0 (en) Compounds
GB0603129D0 (en) Compounds
GB0602856D0 (en) Compounds

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20170626